Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has received approval from the National Medical Products Administration (NMPA) for the registration of its compound sodium lactate Ringer’s injection. The product, classified as a Class 3 chemical drug, has been granted marketing approval and is considered to have passed consistency evaluation.
The compound sodium lactate Ringer’s injection is indicated for the replenishment of extracellular fluid in cases of reduced circulating blood volume and interstitial fluid, as well as for the correction of metabolic acidosis. Humanwell Healthcare has entrusted the production of this injection to its wholly-owned subsidiary, Yichang Sanxia Pharmaceutical Co., Ltd .
The launch of the compound sodium lactate Ringer’s injection diversifies the company’s product portfolio, enhancing its market competitiveness and brand influence. The company will actively promote the marketing and sales of this product moving forward.- Flcube.com
